New technology unlocks ultra-sensitive biomarker detection with the potential to advance the diagnosis and treatment of neurological diseases
Business Wire | November 10, 2017
September 7, 2017
Discussion will be led by Dr. Edward Wild and Lauren Byrne from the UCL Institute of Neurology, with introductory remarks from Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
Quanterix’ CEO to Host Webinar on the Importance of Biomarkers for the Transformation of Precision Health
June 22, 2017
CEO and Chairman, Kevin Hrusovsky, will be hosting a webinar on the use of ultrasensitive biomarker assays to enable precision health, with a specialty focus on concussion and traumatic brain injury (TBI) detection and diagnostics. Hrusovsky will be joined by Dr. Jessica Gill, Investigator at…
Quanterix to Unveil Groundbreaking Neurodegenerative Disease Research and Strategic Partnership at Neuroscience 2016
November 15, 2016
Researchers will present key findings on the development of sensitive predictive biomarkers to establish therapeutic strategies for neurodegenerative diseases; Company will join forces with UmanDiagnostics to provide an ultrasensitive assay for Nf-L
September 26, 2016
Quanterix announces that it is making a strategic investment in ImmunArray, a molecular diagnostics company advancing the development of novel, multi-marker tests for complex diseases with compelling levels of accuracy.
August 1, 2016
Quanterix announces a license agreement for research use with Banyan Biomarkers, a pioneering company in the development of biomarkers for traumatic brain injury (TBI).
Quanterix Presented Ultrasensitive Technology at NFL Health and Safety Update & Interactive Head Health Showcase
February 5, 2016
Quanterix announces that is participating in the NFL Health and Safety Update & Interactive Head Health Showcase at Super Bowl 50.
LEXINGTON, MA – October 6, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the publication of a collaborative whitepaper that addresses concussion management, science, policy…
National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury
LEXINGTON, MA – August 3, 2015 Quanterix Corporation, a leader in high definition diagnostics, today announced that JAMA Neurology has published a new study in which its Simoa (single molecule array) technology was used to identify a protein previously linked to acute symptoms following a traumatic…
LEXINGTON, MA – July 23, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced it was named a final winner of GE and the NFL’s Head Health Challenge I’s phase two grant. There were…